iBio, Inc.
- Tickers
- IBIO
- Headquarters
- Not recorded
- SEC CIK
- 0001420720
- Website
- Not recorded
Closing prices
Latest close, 0.81
| Date | Close |
|---|---|
| 1.76 | |
| 1.53 | |
| 1.44 | |
| 1.39 | |
| 1.32 | |
| 1.29 | |
| 1.24 | |
| 1.25 | |
| 1.15 | |
| 1.16 | |
| 1.10 | |
| 1.21 | |
| 1.09 | |
| 1.00 | |
| 1.05 | |
| 1.11 | |
| 1.17 | |
| 1.20 | |
| 1.23 | |
| 1.10 | |
| 1.07 | |
| 1.04 | |
| 1.28 | |
| 1.20 | |
| 1.67 | |
| 2.22 | |
| 2.81 | |
| 2.42 | |
| 1.94 | |
| 1.83 | |
| 2.06 | |
| 1.89 | |
| 1.88 | |
| 1.98 | |
| 2.01 | |
| 1.88 | |
| 1.87 | |
| 1.89 | |
| 1.85 | |
| 1.71 | |
| 1.93 | |
| 2.02 | |
| 1.88 | |
| 2.06 | |
| 2.17 | |
| 2.35 | |
| 2.70 | |
| 2.70 | |
| 2.54 | |
| 2.49 | |
| 2.21 | |
| 2.20 | |
| 2.24 | |
| 2.24 | |
| 2.39 | |
| 2.25 | |
| 2.15 | |
| 2.28 | |
| 2.23 | |
| 2.15 | |
| 2.10 | |
| 2.30 | |
| 2.24 | |
| 2.20 | |
| 2.15 | |
| 2.42 | |
| 2.41 | |
| 2.27 | |
| 2.21 | |
| 2.11 | |
| 2.22 | |
| 2.29 | |
| 2.33 | |
| 2.45 | |
| 2.38 | |
| 2.45 | |
| 2.47 | |
| 2.87 | |
| 3.07 | |
| 2.82 | |
| 2.69 | |
| 2.69 | |
| 2.83 | |
| 2.64 | |
| 2.61 | |
| 2.50 | |
| 2.38 | |
| 2.43 | |
| 2.49 | |
| 2.45 | |
| 2.39 | |
| 2.46 | |
| 2.19 | |
| 2.10 | |
| 2.09 | |
| 2.21 | |
| 2.08 | |
| 2.18 | |
| 1.74 | |
| 1.76 | |
| 1.71 | |
| 1.90 | |
| 1.95 | |
| 1.98 | |
| 2.03 | |
| 2.11 | |
| 2.24 | |
| 2.20 | |
| 2.16 | |
| 2.20 | |
| 2.19 | |
| 2.10 | |
| 2.11 | |
| 2.06 | |
| 1.97 | |
| 1.92 | |
| 1.92 | |
| 1.81 | |
| 1.68 | |
| 1.71 | |
| 1.63 | |
| 1.62 | |
| 1.69 | |
| 1.59 | |
| 1.58 | |
| 1.61 | |
| 1.77 | |
| 1.64 | |
| 1.71 | |
| 1.66 | |
| 1.61 | |
| 1.55 | |
| 1.56 | |
| 1.47 | |
| 1.42 | |
| 1.50 | |
| 1.70 | |
| 1.89 | |
| 1.84 | |
| 1.82 | |
| 1.88 | |
| 1.93 | |
| 1.90 | |
| 1.89 | |
| 1.76 | |
| 1.84 | |
| 1.93 | |
| 1.82 | |
| 1.73 | |
| 1.70 | |
| 1.70 | |
| 1.67 | |
| 1.69 | |
| 1.65 | |
| 1.55 | |
| 1.60 | |
| 1.69 | |
| 1.74 | |
| 1.65 | |
| 1.62 | |
| 1.59 | |
| 1.67 | |
| 1.73 | |
| 1.75 | |
| 1.75 | |
| 1.68 | |
| 1.62 | |
| 1.59 | |
| 1.52 | |
| 1.51 | |
| 1.51 | |
| 1.45 | |
| 1.44 | |
| 1.43 | |
| 1.35 | |
| 1.38 | |
| 1.37 | |
| 1.41 | |
| 1.38 | |
| 1.40 | |
| 1.43 | |
| 1.45 | |
| 1.39 | |
| 1.36 | |
| 1.39 | |
| 1.40 | |
| 1.42 | |
| 1.46 | |
| 1.40 | |
| 1.39 | |
| 1.41 | |
| 1.40 | |
| 1.47 | |
| 1.47 | |
| 1.40 | |
| 1.43 | |
| 1.45 | |
| 1.45 | |
| 1.49 | |
| 1.47 | |
| 1.43 | |
| 1.42 | |
| 1.47 | |
| 1.43 | |
| 1.40 | |
| 1.36 | |
| 1.27 | |
| 1.26 | |
| 1.31 | |
| 1.30 | |
| 1.31 | |
| 1.30 | |
| 1.26 | |
| 1.23 | |
| 1.21 | |
| 1.20 | |
| 1.19 | |
| 1.18 | |
| 1.25 | |
| 1.28 | |
| 1.26 | |
| 1.33 | |
| 1.25 | |
| 1.20 | |
| 1.19 | |
| 1.17 | |
| 1.17 | |
| 1.18 | |
| 1.11 | |
| 1.13 | |
| 1.12 | |
| 1.05 | |
| 1.01 | |
| 0.92 | |
| 0.87 | |
| 0.90 | |
| 0.78 | |
| 0.78 | |
| 0.78 | |
| 0.77 | |
| 0.76 | |
| 0.82 | |
| 0.84 | |
| 0.78 | |
| 0.72 | |
| 0.71 | |
| 0.77 | |
| 0.80 | |
| 0.81 |
Drugs
No drugs from this company are tracked yet.
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 100,000 USD | 1 Jul 2025 to 30 Jun 2026 FY2026 | 10-K for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −7,730,000 USD | 1 Jan 2026 to 31 Mar 2026 FY2026 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 19,643,000 USD | 1 Jul 2025 to 30 Jun 2026 FY2026 | 10-K for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | 35,241,000 USD | 1 Jul 2025 to 30 Jun 2026 FY2026 | 10-K for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 56,395,000 USD | At 30 Jun 2026 FY2026 | 10-K for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | 31,644,000 USD | At 30 Jun 2026 FY2026 | 10-K for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed |
| Total liabilities | 13,397,000 USD | At 30 Jun 2026 FY2026 | 10-K for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 85,713,000 USD | At 30 Jun 2026 FY2026 | 10-K for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 64,307,256 shares | At 27 Aug 2026 FY2026 | 10-K for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jul 2025 to 30 Jun 2026 FY2026 | 100,000 USD | 10-K filed 28 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2025 to 31 Dec 2025 FY2026 Q2 | 0 USD | 10-Q filed 10 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2025 to 30 Sep 2025 FY2026 Q1 | 100,000 USD | 10-Q/A filed 17 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2024 to 30 Jun 2025 FY2026 | 400,000 USD | 10-K filed 28 Aug 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2025 to 31 Mar 2025 FY2025 Q3 | 0 USD | 10-Q filed 2 May 2025 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2024 to 31 Dec 2024 FY2026 Q2 | 200,000 USD | 10-Q filed 10 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2024 to 30 Sep 2024 FY2026 Q1 | 0 USD | 10-Q/A filed 17 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2023 to 30 Jun 2024 FY2025 | 225,000 USD | 10-K filed 5 Sep 2025 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
- Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect (opens in a new tab)
- Duration of single-agent perioperative antibiotic prophylaxis and postoperative meningitis after endoscopic endonasal skull base surgery: a systematic review and meta-analysis of 7,981 patients. (opens in a new tab)
- Modulation of the gut microbiome and resistome by antibiotic use, but not by subsequent 2'-fucosyllactose intake, in adults with overweight or obesity. (opens in a new tab)
Insider transactions
All rows for iBio, Inc. on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.